| 0.4299 0.013 (3.12%) | 07-14 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 0.54 |
1-year : | 0.64 |
| Resists | First : | 0.46 |
Second : | 0.54 |
| Pivot price | 0.42  |
|||
| Supports | First : | 0.41 |
Second : | 0.37 |
| MAs | MA(5) : | 0.42 |
MA(20) : | 0.42 |
| MA(100) : | 0.81 |
MA(250) : | 1.13 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 41 |
D(3) : | 47.6 |
| RSI | RSI(14): 38.6 |
|||
| 52-week | High : | 2.08 | Low : | 0.37 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ HRTX ] has closed below upper band by 45.5%. Bollinger Bands are 89% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 14 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.44 - 0.44 | 0.44 - 0.44 |
| Low: | 0.4 - 0.4 | 0.4 - 0.4 |
| Close: | 0.43 - 0.43 | 0.43 - 0.43 |
Heron Therapeutics, Inc. is a biotechnology firm dedicated to creating innovative therapies for critical patient requirements. The company leverages its proprietary Biochronomer drug delivery platform, an advanced system that enables the controlled release of various short-acting pharmacological agents. This technology ensures therapeutic concentrations are maintained for periods ranging from days to weeks following just a single administration. Among its commercialized products is SUSTOL (granisetron), an extended-release injectable designed to prevent both immediate and delayed nausea and vomiting triggered by moderately emetogenic chemotherapy, or specific anthracycline and cyclophosphamide combination therapies. Additionally, Heron markets CINVANTI, an intravenous formulation of aprepitant. CINVANTI, which acts as a substance P/neurokinin-1 receptor antagonist, is indicated for the prevention of acute and delayed chemotherapy-induced nausea and vomiting in patients undergoing highly or moderately emetogenic cancer chemotherapy. The company's development pipeline includes ZYNRELEF, an innovative dual-acting local anesthetic that combines bupivacaine, a local anesthetic, with a low dose of the nonsteroidal anti-inflammatory drug (NSAID) meloxicam in a single fixed-dose formulation. Also in development is HTX-019, an experimental therapy aimed at preventing postoperative nausea and vomiting (PONV). Furthermore, HTX-034 is being advanced for postoperative pain management and is currently undergoing Phase Ib/II clinical trials, notably in patients recovering from bunionectomy procedures. Originally established in 1983 as A.P. Pharma, Inc., the company adopted its current name, Heron Therapeutics, Inc., in January 2014. Its corporate headquarters are situated in San Diego, California.
Sun, 12 Jul 2026
Heron Therapeutics, Inc. (NASDAQ:HRTX) Receives Consensus Rating of "Hold" from Brokerages - MarketBeat
Sat, 11 Jul 2026
Heron Therapeutics (HRTX) Stock Sees Fair Value Cut After Cinvanti Patent Decision - Yahoo Finance
Fri, 10 Jul 2026
HRTX Stock Price, Quote & Chart - ChartMill
Tue, 30 Jun 2026
Is Heron Therapeutics, Inc. (HRTX) Stock a Recovery Opportunity After Cinvanti Patent Court Ruling? - Yahoo Finance
Thu, 25 Jun 2026
HRTX Forecast — Price Target — Prediction for 2027 - TradingView
Thu, 25 Jun 2026
Nasdaq warns Heron Therapeutics (NASDAQ: HRTX) on sub-$1.00 bid price - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 189 (M) |
| Shares Float | 134 (M) |
| Held by Insiders | 0.8 (%) |
| Held by Institutions | 84.1 (%) |
| Shares Short | 41,150 (K) |
| Shares Short P.Month | 36,830 (K) |
| EPS | -0.12 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.07 |
| Profit Margin | -13.1 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -0.7 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | -0.5 % |
| Gross Profit (p.s.) | 0.59 |
| Sales Per Share | 0.82 |
| EBITDA (p.s.) | -0.01 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -28 (M) |
| Levered Free Cash Flow | -28 (M) |
| PE Ratio | -3.59 |
| PEG Ratio | 0 |
| Price to Book value | 6.14 |
| Price to Sales | 0.52 |
| Price to Cash Flow | -2.94 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|